Development and dosimetric verification of static SHArc: Step‐and‐shoot carbon ion arc therapy for LET d escalation in pancreatic tumors
Rattachement africain : de, jp, it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Background Carbon ion radiotherapy (CIRT) offers higher linear energy transfer (LET) and superior relative biological effectiveness, making it a promising option for treating hypoxic, radioresistant tumors. Spot‐scanning Hadron Arc (SHArc) therapy enables dose‐averaged LET (LET d ) escalation in the tumor but increases planning and setup complexity. Dynamic delivery remains impractical for gantry‐based carbon ion arc therapy due to the system's large size and complex control requirements. Step‐and‐shoot delivery, while less efficient, provides a feasible alternative and represents a key step towards clinical SHArc implementation. Purpose This work establishes the first step‐and‐shoot planning and delivery technique for carbon ion arc therapy (static SHArc) at the Heidelberg Ion‐beam Therapy Center using the gantry system. Static SHArc therapy is evaluated in terms of plan quality and delivery feasibility for pancreatic cancer. Methods Static SHArc plans were optimized for seven pancreatic cancer cases, considering 20 gantry angles. Two distinct energy layer (EL) selection techniques were investigated: (1) Central EL, selecting the seven central ELs per beam, and (2) MU‐Based EL, prioritizing ELs contributing the highest monitor units (MU). LET d optimization was performed to escalate the minimum LET d to ∼50–80 keV/µm within the gross tumor volume. Static SHArc plans were compared against conventional IMPT using two single‐field optimized posterior oblique beams (2‐SFO), in terms of dose conformality, LET d , and robustness against setup (5 mm) and range (1.5%) uncertainties. Inter‐fractional robustness was assessed via forward dose calculation on daily control CT scans. Dosimetric validation and delivery time verification for static SHArc using the heavy ion gantry system were conducted via end‐to‐end testing with ion chamber and film measurements in a cylindrical PMMA phantom. Results Static SHArc plans improved LET d distributions in the tumor without compromising target coverage and clinical OAR constraints. The MU‐based EL method increased minimum target dose, whereas Central EL enabled higher LET d concentration in the tumor center. Both energy selection methods for static SHArc exhibited reduced inter‐fractional robustness compared to the two‐SFO. Dosimetric verification showed deviations < 3% and total delivery time was ∼27 min. Conclusions This study investigates static SHArc, a step‐and‐shoot approach for delivering carbon ion arc therapy. While static SHArc can provide dosimetric advantages, particularly in terms of LET d distribution, EL selection plays a key role. Improving inter‐fraction robustness remains crucial for clinical implementation.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- Development and dosimetric verification of static SHArc: Step‐and‐shoot carbon ion arc therapy for LET <sub>d</sub> escalation in pancreatic tumors
- Date Crossref
- 01/10/2025
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
German Cancer Research Center pays non établi dans la noticeStructure de recherche
-
Heidelberg University pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Heidelberg pays non établi dans la noticeÉtablissement de santé
-
Heidelberger Institut für Radioonkologie pays non établi dans la noticeInstitution
-
National Institutes for Quantum Science and Technology pays non établi dans la noticeStructure de recherche
-
National Center for Tumor Diseases pays non établi dans la noticeOrganisme public
-
National Center for Oncological Hadrontherapy pays non établi dans la noticeOrganisation à but non lucratif
-
Heidelberg Ion‐Beam Therapy Center (HIT) Department of Radiation Oncology Heidelberg Germany pays non établi dans la noticeInstitution
-
Heidelberg Institute of Radiation Oncology (HIRO) Heidelberg Germany pays non établi dans la noticeStructure de recherche
-
Centro Nazionale di Adroterapia Oncologica (CNAO) Pavia Italy pays non établi dans la noticeInstitution
German Cancer Research Center, Heidelberg University et University Hospital Heidelberg, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.